

Curriculum Vitae



Dr. Yeshwant Kurhe 19840124-6890

Postal address: Department of Medical Biochemistry and Cell Biology, Sahlgrenska Academy, University of Gothenburg, Medicinargatan 9A, SE 413 90 Gothenburg, Sweden

Phone: +46 734 76 5046; Email: yeshwant.vijay.kurhe@gu.se

Short summary

Academic excellence in applied and translational research combined with experience from biotech industry. Since 2018, postdoctoral fellow with the focus on studies of metabolic disorders. First author of 10 high-impact publications; total number of publications 26; *h*-index 16. Main applicant of research grants awarded in international competition. Served as peer reviewer for the journals *J Affect Disord*, *Psychopharmacology*, *Neuropsychopharmacology*, *Clin Exp Pharmacol Physiol*. Excellent team player with exceptional time management skills and passion to contribute to identification of novel treatment targets in the areas of high-unmet medical need.

Present position

2020-pres. Postdoctoral Research Fellow at the Department of Medical Biochemistry and Cell Biology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

Previous positions and periods of appointment

2018-2020 Postdoctoral Research Fellow at the Department of Chemistry and Molecular Biology, University of Gothenburg, Sweden

2017-2018 Research Scholar through the US Department of State J-1 Exchange Visitor Program at the Department of Anatomy and Cell Biology at University of Illinois at Chicago, IL, United States

2012-2017 Ph.D. Research Scholar at the Department of Pharmacy, BITS Pilani, Pilani Campus, Rajasthan, India

2010-2012 Research Executive in Inflammatory, Respiratory and Autoimmune diseases at Drug Discovery-Orchid Research Lab. Ltd, Chennai, India

2009-2010 Lecturer in Pharmacology at RMP'S Bhalchandra College of Pharmacy, Pune, Maharashtra, India

Professional preparation

2018 Ph.D. in Pharmacology, BITS Pilani University, Rajasthan, India

2009 M.Sc. in Pharmacology, Rajiv Gandhi University of Health Sciences, Karnataka, India

2006 B.Sc. in Pharmaceutical Sciences, Pune University, Pune, Maharashtra, India

Recent research awards and grants

1. Research support grants (2019-2020) from Kungl Vetenskaps- och Vitterhets-Samhället (KVVS), Stiftelsen Wilhelm och Martina Lundgrens Vetenskapsfond, Långmanska Kulturfonden Sigurd och Elsa Goljes Minne for (i) Molecular pathogenesis and new treatment strategies for NASH related hepatocellular carcinoma (ii) The role of MST3 kinase in NASH pathology University of Gothenburg, Gothenburg, Sweden.
2. Support grants from Society for Neuroscience-International Brain Research Organization (SfN-IBRO), United States-Paris, (2016), International Brain Research Organization-Asia Pacific Regional Committee (IBRO-APRC), Paris-India, (2015), and Indian Council of Medical Research (ICMR), India (2014).

List of key publications

1. **Kurhe Y**, Caputo M, Cansby M, Xia Y, et al., (2022). Antagonizing STK25 Signalling Suppresses the Development of Hepatocellular Carcinoma through Targeting Multiple Metabolic, Inflammatory, and Pro-Oncogenic Pathways. *Cellular and Molecular Gastroenterology and Hepatology* (IF 9.2), 13:405-423.
2. **Kurhe Y**, Caputo M*, Kumari S, Amrutkar M, et al., (2021). Silencing of STE20-Type Kinase MST3 in Mice with Antisense Oligonucleotide Treatment Ameliorates Diet-Induced Nonalcoholic Fatty Liver Disease. (*Equal contribution) *FASEB J* (IF 5.6), 35:E21567.
3. Szydzik J, Lind DE, Arefin B, **Kurhe Y**, et al. (2021). ATR inhibition enables complete tumour regression in ALK-driven NB mouse models. *Nature Communications* (IF 14.9), 12:6813.
4. Nerstedt A, **Kurhe Y**, Cansby E, Caputo M, et al., (2020). Lipid Droplet-Associated Kinase STK25 Regulates Peroxisomal Activity and Metabolic Stress Response in Steatotic Liver. *J Lipid Res* (IF 4.5), 61:178-191.
5. Caputo M, Cansby E, Kumari S, **Kurhe Y**, et al., (2021). STE20-Type Protein Kinase MST4 Controls Liver Lipid Storage and NAFLD Progression by Regulating Lipid Droplet Dynamics and Metabolic Stress in Hepatocytes. *Hepatol Communication* (IF 5.0), 16:1183-1200.
6. Cansby E, Kulkarni NM, Magnusson E, **Kurhe Y**, et al., (2019). Protein kinase MST3 modulates lipid homeostasis in hepatocytes and correlates with nonalcoholic steatohepatitis in humans. *FASEB J* (IF 5.6), 33:9974-9989.
7. **Kurhe Y**, Mahesh R, Devadoss T. (2017). Novel 5-HT3 receptor antagonist QCM-4 attenuates depressive-like phenotype associated with obesity in high fat diet fed mice. *Psychopharmacology* (IF 3.8), 234:1165-1179.
8. **Kurhe Y**, Mahesh R. (2016). Pioglitazone, a PPAR- γ agonist rescues depression associated with obesity using chronic unpredictable mild stress model in experimental mice. *Neurobiol Stress* (IF 5.2), 3: 114-121.
9. **Kurhe Y**, Mahesh R. (2015). Ondansetron attenuates co-morbid depression and anxiety associated with obesity by inhibiting the biochemical alterations and improving serotonergic neurotransmission. *Pharmacol Biochem Behav* (IF 2.7), 136:107-116.
10. **Kurhe Y**, Mahesh R, Gupta D. (2014). Ondansetron attenuates depression co-morbid with obesity in obese mice subjected to chronic unpredictable mild stress; an approach using behavioral battery tests. *Metab Brain Dis* (IF 2.6), 29: 701-710.
11. **Kurhe Y**, Mahesh R, Gupta D. (2014). Effect of a Selective Cyclooxygenase Type 2 Inhibitor Celecoxib on Depression Associated with Obesity in Mice: An Approach Using Behavioral Tests. *Neurochem Res* (IF 3.0), 39: 1395-1402.